HC Wainwright Has Positive Forecast for DTIL FY2027 Earnings

Precision BioSciences, Inc. (NASDAQ:DTIL) – HC Wainwright increased their FY2027 earnings per share estimates for Precision BioSciences in a report released on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.20 for the year, up from their prior estimate of $0.19. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is $0.82 per share. HC Wainwright also issued estimates for Precision BioSciences’ FY2028 earnings at $0.40 EPS.

Precision BioSciences Stock Up 2.1 %

Shares of NASDAQ:DTIL opened at $8.46 on Wednesday. The company has a market capitalization of $61.17 million, a price-to-earnings ratio of 40.69 and a beta of 1.71. The company has a 50 day moving average of $9.34 and a two-hundred day moving average of $10.06. Precision BioSciences has a 52-week low of $7.97 and a 52-week high of $19.43.

Institutional Investors Weigh In On Precision BioSciences

A hedge fund recently bought a new stake in Precision BioSciences stock. Janus Henderson Group PLC bought a new stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned approximately 8.29% of Precision BioSciences at the end of the most recent reporting period. 37.99% of the stock is owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.